Statement on Reintroduction of Dermatologic Care

Exit strategy list to guide the level of urgency of patient diagnosis groups.

Since about a week, we have been consulted to make an 'exit strategy' list to guide the level of urgency of patient diagnosis groups.
We have discussed this amongst our boards, and decided that every list we make would be insufficient. Dermatologic care is very diverse and even if it is rarely about life and death, skin problems can seriously lower quality of life of a patient.
That is why it is our opinion that each dermatologist should decide on a case by case level, where also e.g. severity of symptoms such as pain and itch ; risk factors such as age, and existing comorbidities but also anxiety level play a decisive role. It speaks for itself that the reintroduction should be done according to COVID-19 practical instructions. Also see the different links below:

  • BADO has made a guideline for the approach in skin cancer .
  • Both the UP and we have consented with other specialists on the reintroduction of esthetic procedures.
  • Advise on the use of immunomodulating agents during this pandemic is on our website.